| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America DM Weber, C Chen, R Niesvizky, M Wang, A Belch, EA Stadtmauer, ... New England Journal of Medicine 357 (21), 2133-2142, 2007 | 1617 | 2007 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1583 | 2015 |
| Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ... Leukemia 22 (2), 414-423, 2008 | 1024 | 2008 |
| A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma S Jagannath, B Barlogie, J Berenson, D Siegel, D Irwin, PG Richardson, ... British journal of haematology 127 (2), 165-172, 2004 | 977 | 2004 |
| The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature WB Bowne, JJ Lewis, DA Filippa, R Niesvizky, AD Brooks, ME Burt, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1999 | 646 | 1999 |
| Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group MA Dimopoulos, E Terpos, A Chanan-Khan, N Leung, H Ludwig, ... Journal of clinical oncology 28 (33), 4976-4984, 2010 | 534 | 2010 |
| Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma MA Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal, EA Stadtmauer, ... Leukemia 23 (11), 2147-2152, 2009 | 504 | 2009 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 437 | 2016 |
| Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial MA Dimopoulos, H Goldschmidt, R Niesvizky, D Joshua, WJ Chng, A Oriol, ... The Lancet Oncology 18 (10), 1327-1337, 2017 | 427 | 2017 |
| Outcome of deferred initial therapy in mantle-cell lymphoma P Martin, A Chadburn, P Christos, K Weil, RR Furman, J Ruan, R Elstrom, ... J Clin Oncol 27 (8), 1209-1213, 2009 | 423 | 2009 |
| International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation M Cavo, SV Rajkumar, A Palumbo, P Moreau, R Orlowski, J Bladé, ... Blood, The Journal of the American Society of Hematology 117 (23), 6063-6073, 2011 | 412 | 2011 |
| International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma M Dimopoulos, E Terpos, RL Comenzo, P Tosi, M Beksac, O Sezer, ... Leukemia 23 (9), 1545-1556, 2009 | 401 | 2009 |
| Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, ... Haematologica 98 (11), 1753, 2013 | 386 | 2013 |
| Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an … SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, ... The Lancet Oncology 15 (13), 1503-1512, 2014 | 322 | 2014 |
| Management of treatment-emergent peripheral neuropathy in multiple myeloma PG Richardson, M Delforge, M Beksaç, P Wen, JL Jongen, O Sezer, ... Leukemia 26 (4), 595-608, 2012 | 310 | 2012 |
| International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem … A Palumbo, SV Rajkumar, JF San Miguel, A Larocca, R Niesvizky, ... Journal of clinical oncology 32 (6), 587, 2014 | 308 | 2014 |
| New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, ... Leukemia 28 (3), 525-542, 2014 | 306 | 2014 |
| A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6 LB Baughn, M Di Liberto, K Wu, PL Toogood, T Louie, R Gottschalk, ... Cancer research 66 (15), 7661-7667, 2006 | 291 | 2006 |
| Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma A Badros, AM Burger, S Philip, R Niesvizky, SS Kolla, O Goloubeva, ... Clinical Cancer Research 15 (16), 5250-5257, 2009 | 285 | 2009 |
| International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma … S Giralt, EA Stadtmauer, JL Harousseau, A Palumbo, W Bensinger, ... Leukemia 23 (10), 1904-1912, 2009 | 277 | 2009 |
